If you have scleroderma, a Roux-en-Y bypass, severe gastroparesis, or years on a proton pump inhibitor, the answer here is straightforward: see a GI specialist, get tested, get treated, and address the underlying cause. If you're an otherwise-healthy adult with bloating and no risk factor, the path is the opposite — be skeptical of any direct-to-consumer breath test you take, skeptical of the "SIBO protocol" industry, and remember that a low-FODMAP trial fixes the same symptoms in most people without an antibiotic.
The small intestine is supposed to be relatively sterile. Three things keep it that way: stomach acid kills most of what you swallow, a sweeping wave of muscle contraction called the migrating motor complex flushes the small bowel between meals roughly every 90 minutes, and the valve at the end of the small intestine stops the dense bacterial population of the colon from washing backward. Break any of the three and bacteria that belong downstream start colonizing upstream Pimentel et al. 2020.
Once they're there, they ferment your food before you do. The hydrogen, methane, and (sometimes) hydrogen sulfide they produce are what makes you feel like a balloon. The same bacteria also strip the molecular tags off bile acids, which wrecks the chemistry needed to absorb fats and the vitamins that ride with them (A, D, E, K), and some of them snatch B12 straight out of the lumen before your gut can grab it. In severe cases the lining of the small bowel itself gets blunted, which makes absorption worse across the board.
One subtype matters enough to have its own name. The organisms that produce methane aren't bacteria at all — they're archaea, mainly Methanobrevibacter smithii, and methane itself is a motility brake: animal work shows it slows small-bowel transit by more than half Pimentel et al. 2006. That's why methane-positive overgrowth — now called intestinal methanogen overgrowth, or IMO — presents as constipation rather than diarrhea, and why the antibiotic that handles regular SIBO doesn't handle this one on its own.
Who actually has it
This is the most important paragraph in the article. If you don't have one of the conditions below, your odds of true SIBO are low enough that a positive breath test is probably noise.
The well-established risk factors, in plain English:
- Scleroderma and other connective-tissue diseases that wreck gut motility. Roughly 38% of scleroderma patients with GI symptoms have aspirate-confirmed overgrowth Marie et al. 2009. Treat aggressively, expect recurrence, plan for cycling.
- Gastric bypass and bowel resections. Roux-en-Y, blind loops left from old surgery, missing ileocecal valve — anatomy that holds food in one place too long or lets colon contents reflux upward.
- Severe gastroparesis. Diabetic autonomic neuropathy, post-vagotomy states, or idiopathic stomach paralysis — anything that disables the cleansing wave.
- Long-term proton pump inhibitor use. Years of omeprazole / pantoprazole / esomeprazole raise overgrowth odds — a meta-analysis of 11 studies put the risk roughly 71% higher in PPI users when SIBO was defined by aspirate or glucose breath test Lo & Chan 2013. Not everyone on a PPI, but real signal in chronic users.
- Advanced cirrhosis with portal hypertension.
- Chronic opioid users with persistent GI symptoms. Opioids slow the small bowel.
What's notably not on this list: being a young otherwise-healthy adult with bloating after meals. The literature is clear that without a predisposing factor, the symptoms readers usually bring to a SIBO workup — bloating, gas, vague abdominal discomfort — are "weakly predictive at best" Quigley et al. 2020. Those readers can still have something treatable. They probably don't have SIBO.
The diagnostic problem
The gold standard is a culture from fluid drawn out of your small intestine through an endoscope — uncomfortable, rarely done, expensive, and contaminated easily by mouth bacteria on the way in. Everyone uses the breath test instead. You drink a sugar solution (glucose or lactulose), the bacteria ferment it, the gases they make cross into your blood, and you exhale them. A nurse collects breath samples every 15 minutes for two hours, and the lab plots the gas curves Rezaie et al. 2017.
Plotted gas curves are a clean idea on paper. The execution is messy.
The fix the field has settled on is the North American Consensus: glucose 75 g or lactulose 10 g, hydrogen rise of 20 ppm or more from baseline within 90 minutes, or methane at or above 10 ppm at any point Rezaie et al. 2017. A third gas — hydrogen sulfide, linked to diarrhea-predominant symptoms — can now be measured by a newer at-home test (Trio-smart) but isn't in the formal guideline thresholds yet.
The practical implication is the one most patients aren't told. If a gastroenterologist tests you for SIBO because you have scleroderma or a Roux-en-Y bypass, a positive result is probably right. If a wellness clinic tests you because you bloat after dinner, a positive result is probably wrong — not because the lab is sloppy, but because that's what a test with these accuracy numbers does in a population where almost no one truly has the disease.
What treatment actually looks like
If the test is positive and the clinical picture fits, the mainstream playbook is short and well-defined. The drug of first choice is rifaximin — a gut-targeted antibiotic that barely gets absorbed into the bloodstream, so it acts locally without the systemic side effects of broader-spectrum options.
The closest thing to a placebo-controlled trial for rifaximin in this space is the pair of TARGET studies in irritable bowel syndrome without constipation — IBS-D, which overlaps heavily with what gets called SIBO. The same 550-mg-three-times-daily regimen for 14 days produced adequate global symptom relief in about 41% of patients versus 32% on placebo, with the benefit holding for ten weeks after the pills stopped Pimentel et al. 2011. That's a real but modest effect — and the only level-1 evidence in the neighborhood.
Two things to do alongside the antibiotic, neither of which is optional in a serious workup. Find and fix the underlying cause if you have one — deprescribe the PPI if you can come off it, treat the gastroparesis, manage the scleroderma. And if you're in a high-risk group, plan for recurrence: about 44% of successfully eradicated patients have a positive breath test again within nine months Lauritano et al. 2008, and that number climbs in older patients, post-gallbladder-removal patients, and chronic PPI users. One lever that costs nothing is meal spacing: grazing all day never lets the migrating motor complex finish a sweep, so leaving a few hours between meals gives that cleaning wave the gap it needs to keep the small bowel flushed.
What the wellness internet gets wrong
SIBO has become a catch-all explanation in functional-medicine circles for fatigue, brain fog, anxiety, rosacea, autoimmune flare-ups, weight that won't budge, and dozens of complaints that don't have a clean diagnosis. The mainstream gastroenterology position, including from authors not known for SIBO skepticism, is that the data don't support those leaps Quigley et al. 2020.
A few specific things worth unlearning:
- A positive breath test is not a diagnosis on its own. It's a piece of evidence whose meaning depends entirely on whether you have a risk factor. Same gas pattern, totally different probability of real disease.
- Lactulose and glucose aren't interchangeable. Lactulose travels further down the bowel and produces something like ten times the positivity rate of glucose in IBS patients — much of that extra positivity is colonic gas, not small-bowel overgrowth.
- "SIBO protocols" that run for months or years aren't treating SIBO. The actual treatment is two weeks of antibiotic. If you've been on rotating herbal antimicrobials, biofilm disruptors, and elimination diets for a year, you've been treating something else — or treating nothing.
- Probiotics aren't established treatment. Some studies show signal, the field is split, and the major guidelines don't recommend them as primary therapy.
- The chronic-fatigue / brain-fog link is unverified. The studies tying SIBO to non-GI symptoms are small, uncontrolled, or absent. Resolving a real malabsorption-driven B12 or iron deficiency improves energy — through the deficiency, not through "SIBO" as a unifying disease.
What to try if you don't fit the picture
If you're a bloater without a risk factor, almost all the evidence on what actually helps is in a different lane — irritable bowel syndrome and functional dyspepsia. The interventions with the strongest evidence:
- Low-FODMAP diet, done properly. A short restriction phase (4–6 weeks) followed by structured reintroduction. Resolves or substantially improves symptoms in roughly half to two-thirds of bloated IBS patients, with the best evidence base of any dietary approach in this space. Done as an indefinite restriction, it backfires — the goal is to find the specific foods that drive your symptoms, then eat normally otherwise.
- Peppermint oil enteric-coated capsules. Cheap, well-tolerated, Cochrane-positive for IBS pain and bloating.
- Gut-directed hypnotherapy or CBT. Sounds soft, has the strongest long-term durability data of any treatment in functional GI.
- A low-dose tricyclic at night. Amitriptyline or nortriptyline 10–25 mg at bedtime, prescribed for "visceral hypersensitivity" — the gut–brain axis route, with real RCT support.
- Prokinetics for constipation-predominant patterns. Prucalopride or, off-label, low-dose erythromycin can resolve the same constipation that gets labeled "methane SIBO" without the antibiotic course.
None of these require a breath test or a $2,000 prescription. If they fix it, the question of whether you ever had SIBO becomes academic.
Costs, coverage, and what to expect
The breath test runs $150 to $400 cash; in-office at a gastroenterology practice can hit $500. The billing code is CPT 91065. Commercial insurance and Medicare cover it inconsistently — some plans call it "experimental." Three-gas testing that adds hydrogen sulfide costs another $50–$100.
The drug is the cost shock. Rifaximin is brand-only in the US until 2029 — Xifaxan 550 mg runs about $2,200 to $3,000 for a 14-day course at retail. Insurance covers it readily for the FDA-approved indications (IBS-D and hepatic encephalopathy) but treats SIBO as off-label, so even when a gastroenterologist prescribes it your plan may require a prior-authorization letter or deny outright. Manufacturer savings cards and SingleCare-style discounts bring the cash price down maybe a third. Neomycin and metronidazole are generic and cheap.
The whole workup — test, treatment, follow-up — fits inside a few weeks if it's going to work. If you're a year into a "SIBO journey" without durable improvement, that's data: either the diagnosis was wrong or it's not the unifying problem you've been told it is.
Where SIBO treatment goes off the rails
- Treating the test, not the patient. A positive breath test in someone with no risk factor and modest symptoms doesn't mean rifaximin is the right answer. Sometimes it works for a few weeks (placebo plus microbiome perturbation), then everything comes back, then the loop starts.
- Skipping the methane question. A hydrogen-only test in a methanogen-positive patient reads negative; the patient stays constipated and starts blaming food. Insist on a test that measures both gases (and ideally hydrogen sulfide).
- Never deprescribing the PPI. If years of acid suppression set up the overgrowth, the antibiotic clears it and the next year of acid suppression sets it up again.
- The DTC kit trap. Order test online, ship saliva and breath, get a report flagging "SIBO," buy a $400 herbal protocol from the same site. The closed loop has the same accuracy problem as the clinical version, with worse advice on top.
- Three rounds and still going. If you've done two well-executed antibiotic courses without durable improvement, the diagnosis is probably wrong. Restart from "what else could explain these symptoms" with a generalist GI, not a fourth round.
Adjacent worth looking at
Topics that frequently sit next to a SIBO question:
- Irritable bowel syndrome. The condition most SIBO breath tests are run for; most of what fixes IBS also fixes the symptoms people attribute to SIBO.
- Low-FODMAP eating. The strongest-evidence dietary intervention in the bloating / functional-GI space.
- Long-term PPI use. Worth its own re-think — the most modifiable SIBO risk factor in the catalogue, and most people on chronic acid suppression don't need to be.
- Gastroparesis and motility disorders. The mechanical root cause behind most non-surgical SIBO.
- Celiac disease. Overlapping symptom profile (bloating, malabsorption, anemia), totally different treatment — worth ruling out before the SIBO workup starts.
- — Years on a proton pump inhibitor is one of the few things that genuinely raises your SIBO risk.
- — Overgrown bacteria grab B12 out of your gut before you can absorb it, so true SIBO can quietly drive a deficiency.
- — A stalled migrating motor complex lets bacteria overgrow; spacing meals four hours apart lets that cleaning wave finish.
- — Before you chase a SIBO diagnosis, know that a low-FODMAP trial fixes the same bloating in most people — no antibiotic.
- — Real SIBO is usually treated with a gut-targeted antibiotic course — worth a plan to recover the microbiome afterward.
- — SIBO is one real cause of stubborn bloating — but only a minority of bloaters actually have it.
- — Slow gut motility is what lets colon bacteria creep upstream — sluggish transit is a real risk factor for overgrowth.
- — IBS and SIBO overlap heavily in symptoms, and a lot of 'SIBO' is really IBS wearing a trendier name.
- — The methane-producing form (IMO) slows the bowel and shows up as constipation, not diarrhea — and needs a different antibiotic combo.
- — SIBO is one of the named causes behind chronic diarrhea wrongly filed as IBS; a breath test can sort it.
Substance + claimed effects
Small intestinal bacterial overgrowth (SIBO) is the proliferation of bacteria — and, separately, methane-producing archaea (intestinal methanogen overgrowth, IMO) — in the small bowel above thresholds normally seen in healthy controls. The historical aspirate cut-off was ≥105 CFU/mL of jejunal fluid; the current North American Consensus and ACG guideline use >103 CFU/mL of coliform bacteria Pimentel et al. 2020. Claimed effects span GI symptoms (bloating, flatulence, abdominal pain, altered stool form), nutrient malabsorption (B12, iron, fat-soluble vitamins A/D/E/K via bile-salt deconjugation), and contribution to IBS — particularly bloating-dominant and constipation-dominant subtypes. This entry covers SIBO end-to-end as a defined clinical condition: who actually has it, how to test, how to treat, the diagnostic-accuracy and over-diagnosis controversy, and the boundary between evidence-based GI care and the wellness-industry version that has grown up around an unreliable test.
Evidence by addressing question
Mechanism
The small intestine maintains low bacterial density (typically <104 CFU/mL) by three defences: gastric acid (kills swallowed organisms), the migrating motor complex (MMC, the fasting-state sweep that flushes the small bowel every ~90 minutes), and the ileocecal valve (stops colonic reflux). Breach any of the three and proximal colonization rises. Established risk factors map cleanly onto these defences Pimentel et al. 2020 Quigley et al. 2020:
- Acid suppression. PPI use raises SIBO prevalence — meta-analysis of 11 studies (n=3,134) shows OR 1.71 (95% CI 1.20–2.43) when SIBO is defined by aspirate or glucose breath test, with stronger association in higher-quality studies Lo & Chan 2013.
- Dysmotility. Scleroderma, diabetic autonomic neuropathy, post-vagotomy states, opioid use, idiopathic gastroparesis — anything that disables the MMC.
- Anatomic. Surgical blind loops, strictures, fistulae, Roux-en-Y, resected ileocecal valve.
Symptoms have two mechanical routes. (1) Bacterial fermentation of dietary carbohydrates in the proximal bowel produces hydrogen and CO2 in the gas phase — the bloating. (2) Bacterial deconjugation of bile acids impairs micelle formation, causing fat maldigestion (steatorrhea) and secondary fat-soluble vitamin loss; bacterial uptake of B12 in the lumen produces a macrocytic-anemia signal. Mucosal damage (villous blunting from enteroadherent organisms) compounds malabsorption. Methane gas itself slows transit in a dose-dependent fashion in animal models — methane infusion into the small intestine of dogs reduced transit by ~59% Pimentel et al. 2006, supplying a mechanistic basis for the IMO–constipation link.
Evidence
The case that SIBO is a real clinical entity in defined populations is uncontested: bacterial overgrowth on aspirate culture in patients with scleroderma, post-surgical blind loops, or severe gastroparesis correlates with steatorrhea, malabsorption, and symptom response to antibiotic decontamination. The contested case is the much larger one of breath-test-positive symptomatic patients without anatomic or motility predisposition, who now make up the majority of SIBO diagnoses Quigley et al. 2020.
Breath-test performance against the aspirate reference is poor. A 2020 meta-analysis of 14 studies (n=1,777) found pooled sensitivity 0.42 (95% CI 0.39–0.45) and specificity 0.91 (95% CI 0.89–0.93) for lactulose breath test; glucose breath test pooled sensitivity 0.55 (95% CI 0.51–0.59) and specificity 0.83 (95% CI 0.80–0.86) Losurdo et al. 2020. Lactulose's higher false-positive rate reflects rapid orocecal transit producing an early "second peak" that is colonic fermentation, not small-bowel overgrowth. The North American Consensus partly addresses this by setting the threshold at ≥20 ppm rise in H2 from baseline by 90 minutes, and ≥10 ppm CH4 at any time Rezaie et al. 2017, but real-world inter-rater agreement and substrate selection remain inconsistent.
Treatment evidence is strongest for rifaximin. Gatta & Scarpignato's meta-analysis pooled 32 studies (n=1,331) and found ITT eradication 70.8% (95% CI 61.4–78.2) and PP eradication 72.9% (95% CI 65.5–79.8); 67.7% of eradicated patients had symptom improvement; adverse-event rate 4.6% with treatment discontinuation 0.47% Gatta & Scarpignato 2017. A 2021 update reported lower pooled eradication (ITT 59%) with dose-dependence — 1,600 mg/day > 1,200 mg/day > 800 mg/day. For IBS-without-constipation (a SIBO-overlap population), the TARGET-1/2 phase-3 RCTs (n=1,260) showed rifaximin 550 mg TID × 14 days produced adequate global IBS relief in 40.7% vs 31.7% placebo (p<0.001), with effect sustained 10 weeks post-treatment Pimentel et al. 2011.
For methane-positive (IMO) patients, monotherapy is less effective. Low et al.'s prospective comparison gave rifaximin 400 mg + neomycin 500 mg BID × 10 days vs either alone; the combination eradicated methane in 87% vs ~30% for rifaximin alone Low et al. 2010. Elemental-diet treatment — 14 days on a hypoallergenic free-amino-acid formula — normalized lactulose breath tests in 80% of patients in Pimentel's original trial (n=124) Pimentel et al. 2004, replicated in more recent open-label work at ~73% normalization. An open-label comparison of an herbal antimicrobial protocol (oregano, berberine, allicin) vs rifaximin in 104 patients showed equivalent breath-test normalization (46% herbal vs 34% rifaximin) Chedid et al. 2014, though without blinding or placebo control.
Recurrence is the dominant treatment-side problem. Lauritano et al. followed 80 rifaximin-eradicated patients and documented breath-test recurrence in 12.6% at 3 months, 27.5% at 6 months, and 43.7% at 9 months Lauritano et al. 2008. Higher in patients ≥65, post-cholecystectomy, or on chronic PPI. No RCT establishes that any specific prokinetic prevents SIBO recurrence in this setting — the prokinetic-post-eradication paradigm rests on expert opinion and small uncontrolled series.
Protocol
The mainstream protocol assembled from ACG and AGA guidance:
- Pre-test the indication. Symptoms (bloating, distention, gas, altered bowels) + a plausible risk factor (prior abdominal surgery, scleroderma, gastroparesis, chronic PPI, severe IBS). Testing low-pretest-probability patients amplifies the false-positive problem given specificity ≤91% Losurdo et al. 2020.
- Test. Glucose 75 g or lactulose 10 g breath test with H2 and CH4 sampling every 15 min for 90–120 min. Glucose is more specific (proximal-jejunal pickup, less colonic contamination); lactulose covers more distal bowel but generates more false positives. ≥20 ppm H2 rise from baseline by 90 min or ≥10 ppm CH4 any time = positive Rezaie et al. 2017. Three-gas testing adding H2S (Trio-smart, FDA-registered) extends coverage to sulfide-producing overgrowth (diarrhea-correlated) — emerging, not yet in formal guidelines.
- Treat hydrogen-positive. Rifaximin 550 mg PO TID × 14 days (the IBS-D and ACG-suggested dose). Eradication ~60–70%, symptom relief ~60% of eradicated Gatta & Scarpignato 2017.
- Treat methane-positive (IMO). Rifaximin 550 mg TID + neomycin 500 mg BID × 14 days, or rifaximin + metronidazole 250 mg TID. Methanogens resist rifaximin monotherapy Low et al. 2010.
- Retreat on recurrence. TARGET-3 established that re-treatment with the same rifaximin regimen at relapse is effective; up to 2 retreatments studied.
- Adjunctive. Address root cause (deprescribe PPI if possible, treat dysmotility), consider low-FODMAP transitionally, address coexisting micronutrient deficiencies (B12, iron, fat-soluble vitamins).
Contraindications
Rifaximin is non-absorbable (<0.4% systemic bioavailability) and FDA-pregnancy category C — generally avoided in pregnancy because of limited human data, though plausibly safer than systemic antibiotics. Neomycin is ototoxic and nephrotoxic with chronic use; the 10–14-day SIBO dose is generally tolerated but contraindicated in pre-existing renal impairment or hearing loss. Metronidazole interacts with alcohol (disulfiram-like reaction) and carries peripheral-neuropathy risk on repeated courses. Breath testing itself is benign; the substrate volume (250 mL water + sugar) can transiently exacerbate symptoms.
Misconceptions
- "A positive breath test means SIBO." Pooled sensitivity 0.42–0.55 and specificity 0.83–0.91 against aspirate Losurdo et al. 2020. In a 30%-prevalence population the positive predictive value is roughly 70%; in a 10%-prevalence population (low-pretest IBS without dysmotility), PPV falls to ~40%. The test is most useful at narrowing in a pre-selected population, not as a screen.
- "SIBO is the cause of my chronic fatigue / brain fog / rosacea / autoimmune disease." Outside GI symptoms and malabsorption, evidence is sparse to absent. The AGA Clinical Practice Update specifically warns against the breadth of conditions to which SIBO is attributed in lay press Quigley et al. 2020.
- "Eradication = cure." Recurrence is ~44% by 9 months without root-cause correction Lauritano et al. 2008.
- "Probiotics treat SIBO." Mixed evidence; a meta-analysis suggested ~53% eradication signal, but heterogeneity is severe and trial quality low. AGA does not recommend.
- "Lactulose and glucose are interchangeable." Lactulose breath test produces ~10x the positivity rate of glucose in IBS populations because rapid transit creates a colonic-fermentation signal mimicking SIBO.
Audience
Populations where SIBO is genuinely common and worth aggressive workup: systemic sclerosis (~38% prevalence in symptomatic patients Marie et al. 2009), post-Roux-en-Y bariatric surgery, post-bowel-resection with anatomic alterations, severe gastroparesis (diabetic or idiopathic), advanced cirrhosis with portal hypertension, chronic-opioid users with persistent GI symptoms. Populations where SIBO labels are overused: young adults with bloating and no risk factors, patients who have already cycled through "SIBO protocols" without symptom durability, anyone whose breath-test diagnosis came from a direct-to-consumer kit interpreted without clinical context.
Alternatives
For the typical bloating/IBS-overlap patient, well-evidenced alternatives that often resolve the same complaint without invoking SIBO: low-FODMAP diet (NICE/BDA-supported, ~50–70% IBS symptom response), neuromodulators (low-dose TCAs for visceral hypersensitivity), peppermint oil enteric capsules (Cochrane-positive for IBS pain), CBT/gut-directed hypnotherapy. For methane-positive constipation specifically: prokinetics (prucalopride 1–2 mg daily, low-dose erythromycin) and osmotic laxatives may produce comparable symptom benefit without antibiotic exposure.
Failure-modes
- Treating a false-positive breath test with antibiotics. Patient gets transient placebo + non-specific gut-microbiome effect of rifaximin, symptoms relapse, cycle repeats.
- Not addressing root cause. PPI never deprescribed, motility issue never named, scleroderma never recognized.
- Missing IMO. Hydrogen-only test in a methane producer reports "negative" — the patient stays constipated.
- Endless cycling. Patients on their 4th or 5th SIBO protocol with no objective improvement are signaling that SIBO is probably not the unifying diagnosis, regardless of breath-test results.
Practicalities
Breath test costs $150–$400 cash; in-office $200–$500; CPT 91065 is increasingly covered by commercial insurance and Medicare with documented medical necessity but many plans still call it "experimental." Rifaximin (Xifaxan 550 mg) has no US generic before 2029 — retail ~$2,200–$3,000 per 14-day course; insurance coverage for the off-label SIBO indication often requires prior authorization with letter of medical necessity. Generic neomycin and metronidazole are inexpensive. Three-gas testing adds $50–$100. Elemental diet formulas (Vivonex, custom-compounded) run ~$200–$400 for a 14-day course and require strict adherence — most patients tolerate poorly.
Stakes
Untreated SIBO in a true high-risk patient (scleroderma, post-surgical blind loop) produces progressive malabsorption: weight loss, B12-deficient macrocytic anemia, fat-soluble vitamin deficits, osteopenia from chronic vitamin D and calcium loss, fatigue, peripheral neuropathy from B12. In the more common breath-test-positive IBS-overlap patient, the "stakes" are mostly continued bloating/discomfort and the iatrogenic cost of repeated antibiotic exposure and unproven supplement regimens.
Payoff
In responders: post-treatment bloating typically resolves within 1–2 weeks, with bowel-habit normalization tracking close behind. ~60% of eradicated patients report sustained symptom improvement at 4–10 weeks Gatta & Scarpignato 2017 Pimentel et al. 2011. In high-risk patients (scleroderma), aggressive cycling treatment can restore weight and nutritional status. Durability is the catch: ~44% recur by 9 months without root-cause work Lauritano et al. 2008.
Out-of-scope
Adjacent topics worth signposting in the article's closing pointers: IBS, low-FODMAP eating, PPI deprescribing, fecal microbiota transplant (no evidence-base in SIBO), small intestinal fungal overgrowth (SIFO — emerging entity, even less standardized).
The credibility range
Optimist case
SIBO is a real, common, under-recognized condition. The MMC story is mechanistically airtight; the populations where aspirate-confirmed overgrowth correlates with steatorrhea and B12 deficiency leave no doubt the entity exists. Breath testing has known imperfections but is the only practical noninvasive option; the North American Consensus standardized thresholds and substrate, and three-gas testing is closing the H2S blind spot. Rifaximin has level-1 RCT evidence in IBS-D (TARGET-1/2; n=1,260) with a clean safety profile Pimentel et al. 2011. The IMO category — with its own pathophysiology and combination-therapy response — is a refinement, not a retreat. The under-diagnosis story is at least as plausible as the over-diagnosis story: many bloated patients are dismissed as "IBS" with no workup, miss a treatable root cause, and cycle through dietary restriction instead of resolving the underlying overgrowth.
Skeptic case
Breath testing has poor sensitivity (≤55%) and imperfect specificity (≤91%) against the aspirate gold standard Losurdo et al. 2020, so its widespread use in low-pretest-probability populations produces a steady stream of false positives — particularly with lactulose, which generates ~10x the positivity rate of glucose because it reaches the colon. The AGA Clinical Practice Update by Quigley, Murray & Pimentel notes that the entity's definition "lacks precision and consistency" and that symptoms are "weakly predictive at best" without obvious predisposing factors Quigley et al. 2020. The rifaximin signal in IBS may be a non-specific microbiome-modulation effect rather than SIBO eradication per se — the placebo-control delta in TARGET (40.7% vs 31.7%) is ~9 percentage points, real but modest, and most patients eventually relapse Pimentel et al. 2011. Commercial incentives are non-trivial: Mark Pimentel — author of the ACG guideline, the North American Consensus, the elemental-diet trial, the IMO terminology, and Trio-smart's research lead — has consulted for or received support from Salix (manufactures rifaximin) and Gemelli Biotech (sells Trio-smart). The lay-press/wellness-industry version of SIBO blames it for fatigue, brain fog, rosacea, autoimmunity, and dozens of other complaints with essentially no controlled evidence.
Author's call
Both true and over-diagnosed. The entity is well-defined and treatable in clear high-risk groups (scleroderma, post-surgical, severe dysmotility, advanced cirrhosis); breath testing in this enriched population is genuinely useful and rifaximin works. Outside that, the test's specificity is too low to drive antibiotic decisions in the population that drives most SIBO diagnoses — bloated, otherwise-well IBS patients with no risk factor. The article should treat SIBO as a real clinical condition with a contested diagnostic infrastructure and lean the reader toward GI specialist evaluation (not a wellness clinic or DTC kit), risk-factor-stratified testing, and skepticism of long-running personal "SIBO protocols" that never durably resolve. evidence ~3 (mechanism solid, RCTs exist but specificity issues meaningful); controversy ~3–4 (active debate, foundational disagreement on test interpretation and over-diagnosis bounds).
Stakeholder + incentive map
- Commercial: Salix Pharmaceuticals (rifaximin; brand Xifaxan; ~$1.5B/year US revenue at peak). Gemelli Biotech (Trio-smart breath test). Cedars-Sinai (patent licensing on lactulose breath-test methodology).
- Academic: Mark Pimentel and the Cedars-Sinai MAST program — productive research output, also commercial entanglement disclosed in every guideline (relevant to weighting the IMO/Trio-smart pipeline).
- Professional bodies: ACG (broadly endorses breath testing and rifaximin Pimentel et al. 2020) vs AGA Clinical Practice Update (more skeptical posture, same primary author Quigley et al. 2020). Rome Foundation runs in the IBS lane and is broadly more cautious on the SIBO–IBS overlap claim.
- Community / wellness: functional-medicine practitioners and DTC labs run high-volume SIBO testing; "SIBO diet" content saturates the wellness internet; herbal-antimicrobial protocols sell well; recurrence-and-retest economics keep patients in long-running relationships.
- Counter-incentive: antimicrobial-stewardship voices, generalist GI practitioners skeptical of breath-test-driven diagnoses, primary-care clinicians who see SIBO labels arrive from wellness clinics and have to manage the aftermath.
Population variability
- High-risk groups (high pretest probability, test pays off): systemic sclerosis (38% in symptomatic Marie et al. 2009), post-bariatric (Roux-en-Y), post-bowel-resection, severe gastroparesis (diabetic or idiopathic), advanced cirrhosis, chronic-opioid users with persistent GI symptoms, the elderly on long-term PPIs.
- Intermediate: IBS with constipation predominance — IMO is enriched in IBS-C and methane testing with combination therapy may genuinely help.
- Low-yield: young otherwise-well adults with bloating, no risk factor, breath-test positive — most likely false positive or a clinically meaningless overgrowth that responds to dietary modification alone.
- Age/sex: Female predominance in IBS-overlap presentations; older age and post-cholecystectomy state both increase recurrence risk after eradication.
Knowledge gaps
- Whether breath-test-positive without aspirate-confirmation is the same disease as aspirate-positive SIBO. Likely a spectrum, but the test-positive-without-risk-factor population is poorly characterized.
- Whether H2S-positive SIBO (intestinal sulfide overproduction) is a distinct treatable entity or a research artifact — early Trio-smart data are promising but no RCT base.
- No RCT confirms that any specific prokinetic prevents SIBO recurrence; the post-eradication paradigm is expert opinion.
- No head-to-head of rifaximin vs herbal protocols beyond the single Chedid open-label trial.
- What "SIBO" actually means at the microbiome level — culture-independent sequencing finds that the small-bowel microbiome of symptomatic vs asymptomatic individuals overlaps heavily, suggesting overgrowth is one phenotype of broader small-bowel dysbiosis rather than a discrete syndrome.
- The evidence that durably resolving SIBO improves any non-GI outcome (fatigue, mood, "brain fog") is essentially absent despite the centrality of these claims in lay discussion.
Scope and framing
The brief named four consequence areas: GI symptoms, nutrient absorption, diagnostic accuracy, and the evidence-based vs over-diagnosed boundary. All four are covered. The article centers on the diagnostic-accuracy and over-diagnosis angle because that's where the catalogue's reader is most likely to be making a real decision (or being talked into a wrong one) — most people encountering "SIBO" first do so through wellness channels rather than a gastroenterologist's office.
Action / cadence call
Picked know rather than test or decide. This entry's primary job is condition literacy — sorting wellness mythology from the real entity. The actual decision to test/treat falls out of recognizing whether you're in the high-risk-factor group, which is a downstream consequence of knowing. Cadence as-needed because workup is symptom-and-risk-triggered, not periodic.
Dimension scoring
- Energy and mood scored 0. Considered scoring both at 1 (downstream of resolved malabsorption / GI symptom relief), but the spec requires non-zero dimensions to get a real paragraph in the body. The article's tightest version treats GI symptom relief as the only direct consequence (
health_short_term: 3) and explicitly debunks the wellness-internet claim that SIBO is the unifying cause of fatigue/brain fog/mood symptoms. Scoring energy or mood non-zero would have softened that posture against the lay-press over-attribution. - Evidence 3, controversy 4. The split is the point — mechanism and treatment have decent data, the diagnostic test that gates everything does not, and major guideline bodies (ACG vs AGA Clinical Practice Update) disagree on how heavily to lean on it. Commercial entanglements (Pimentel / Salix / Gemelli) belong in the controversy score, not the evidence score.
- Cost burden 3. Driven almost entirely by rifaximin's US brand-only status (no generic until 2029). If insurance covers the IBS-D indication, real cost can drop to a 2; without coverage, easily a 3 or even 4.
Excluded
- SIFO (small intestinal fungal overgrowth). Adjacent, less standardized; mentioned in dossier out-of-scope but not in the article. Separate-entry candidate when the evidence base matures.
- Detailed mechanism on hydrogen sulfide. Trio-smart is mentioned in passing; full H2S/ISO story is still in research-translation phase. Worth revisiting in 2–3 years.
- Specific herbal-antimicrobial protocols. Chedid 2014 is cited in dossier but not the article — one open-label trial isn't enough to anchor reader-facing prose, and getting into oregano/berberine/allicin specifics risks the wellness-clinic voice the article is trying to push back against.
- Detailed FMT and probiotic protocols. Probiotics get a one-line dismissal in misconceptions; FMT is absent because the evidence base in SIBO specifically is essentially nil.
Future links
Entries this one should cross-link to as they land: ibs, low-fodmap, ppi-deprescribing, gastroparesis, celiac-disease. All flagged in out-of-scope section. methane-imo could become its own entry if the field's IMO-as-separate-syndrome direction holds.
Conflict-of-interest note for reviewer
Most of the SIBO literature this entry rests on shares an author (Mark Pimentel of Cedars-Sinai) with significant commercial disclosures to Salix (rifaximin manufacturer) and Gemelli Biotech (Trio-smart test). The article is honest about this in dossier and reflects it in the controversy score; reviewer should sanity-check that the article's framing isn't unwittingly amplifying the commercial-pipeline view. The AGA Clinical Practice Update Quigley et al. 2020 (also Pimentel-authored, but more skeptical in tone) is the counterweight cited throughout.
Tone choices
The dek and headline lean harder into the "real condition, fake test" framing than a neutral textbook would. Defensible because the catalogue's reader is far more likely to encounter SIBO over-diagnosis than under-diagnosis — the priors run that direction. A reader in a true high-risk group (scleroderma, post-bariatric) gets a clear signal in the audience section that the framing flips for them.
SIBO (Bacterial Overgrowth)
A 14-day antibiotic course three times daily, preceded by a fasting breath test, optionally followed by short-term dietary modification and prokinetic use. Bounded course, not a daily lifelong habit — but real adherence demand during treatment.
When SIBO is correctly diagnosed and treated, bloating, distention, gas, and altered stool form resolve over 1–2 weeks. Rifaximin meta-analysis of 32 studies (n=1,331) reports symptom improvement in ~68% of patients with eradicated overgrowth (Gatta & Scarpignato 2017); TARGET-1/2 RCTs (n=1,260) show a 9-percentage-point absolute benefit over placebo on global IBS-D relief sustained 10 weeks post-treatment (Pimentel et al. 2011).
Breath test $150–$400 cash; rifaximin (Xifaxan 550 mg) retail $2,200–$3,000 for a 14-day course with no US generic until 2029, and off-label-for-SIBO coverage often requires prior authorization. Recurrence (~44% by 9 months, Lauritano et al. 2008) means many patients face repeat costs. Lower if insurance covers the IBS-D indication.
Mechanism is solid (acid suppression / dysmotility / anatomic risk factors map cleanly to defended barriers). Rifaximin has phase-3 RCT support in the closely-related IBS-D indication (TARGET-1/2; Pimentel et al. 2011). But the diagnostic infrastructure is the weak link: pooled breath-test sensitivity 0.42–0.55 against aspirate gold standard (Losurdo et al. 2020), and the ACG guideline rests largely on 'very low level of evidence' conditional recommendations (Pimentel et al. 2020).